Skip to content
DataLookout
Menu

BeOne Medicines clinical trial pipeline

Get alerts when BeOne Medicines's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

11 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 5 with minor changes only.

  1. Notable: Investigational Study of BG-75202 Alone and in Combination With Other Agents · Advanced Solid Tumors Enrollment increased: 86 → 186 participants BeOne MedicinesPhase 1 NCT07222267
  2. Notable: BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma Recruitment opened BeOne MedicinesPhase 3 NCT07836530
  3. Notable: Tacabrutideg (BGB-16673) · Moderate and Severe Hepatic Impairment Start date pushed from Oct 22, 2026 to Dec 2026 BeOne MedicinesPhase 1 NCT07856004
  4. Minor: Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib · Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) Trial sites reduced: 150 → 145 locations BeOne MedicinesPhase 3 NCT06742996
  5. Notable: BG-C477 · Advanced Solid Tumors Primary and study completion pushed from Dec 31, 2027 to Jul 23, 2028 BeOne MedicinesPhase 1 NCT06596473
  6. Minor: KANDELA-302 · BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole · Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease Trial sites expanded: 206 → 241 locations BeOne MedicinesPhase 3 NCT07492641
  7. Minor: Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma Trial sites reduced: 77 → 74 locations BeOne MedicinesPhase 1/2 NCT04973605
  8. Minor: Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults Trial completed BeOne MedicinesPhase 1 NCT07628881
  9. Notable: Treatment · B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader Sponsor changed: BeiGene to BeOne Medicines BeOne MedicinesPhase 1/2 NCT05294731
  10. Notable: Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents · Advanced Solid Tumors Primary and study completion pushed from Sep 30, 2027 to Aug 31, 2028 BeOne MedicinesPhase 1 NCT06589596
  11. Minor: Sonrotoclax · Severe Hepatic Impairment Start date pushed from Oct 15, 2026 to Nov 2026 BeOne MedicinesPhase 1 NCT07855991
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-12 NCT07934069 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food… Phase 1 Not Yet Recruiting
2026-11-03 NCT07911683 Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced… Phase 2 Not Yet Recruiting
2026-10-29 NCT07904845 A Study of BON-C1393 in Adults With Advanced Solid Tumors Phase 1 Not Yet Recruiting
2026-10-27 NCT07896460 A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents… Phase 1 Not Yet Recruiting
2026-10-26 NCT07893535 An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors Phase 1 Not Yet Recruiting
2026-10-21 NCT07887646 A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody… Phase 1 Not Yet Recruiting

Active trials by phase

Phase 1
29
Phase 1/2
9
Phase 2
5
Phase 2/3
1
Phase 3
14
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 19

Get alerts when BeOne Medicines's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free